Mckesson and aetion collaborate to advance cancer research with real-world data

Aetion and mckesson announced a strategic collaboration focused on advancing the use of real-world evidence (rwe) in cancer research to benefit patients, regulators, the biopharma industry, and payers. the partnership will provide best-in-class solutions in multiple tumor types, including breast, lung, and melanoma cancers. the joint solutions combine the aetion evidence platform™ with data from mckesson’s iknowmedsm oncology electronic health record (ehr) system to power regulatory-grade outcomes research. they will first be made available to the team of researchers at brigham and women’s hospital who are leading the food and drug administration (fda) demonstration project, rct duplicate, in order to replicate oncology randomized controlled trials (rcts) with real-world data. aetion and mckesson are also both part of the friends of cancer researchreal-world evidence pilot project to assess several frontline treatment regimens in real-world patients with advanced non-small cell lung cancer (ansclc), which will inform the fda's acceptance of real-world evidence for drug approvals. the solutions allow users to conduct regulatory-grade studies in major cancers and accelerate time to insight on oncology data. it also enables researchers to develop evidence for synthetic control arm and label expansion studies, to fulfill post-marketing safety requirements, and to assess the economic impact of treatments.
MCK Ratings Summary
MCK Quant Ranking